TECH · NMS
S&P 500
Bio-Techne Corporation
Healthcare · Biotechnology
$72.82
−$0.01 (−0.01%) today
Closing price on Nov 10, 2026 · Source: Yahoo Finance
Consensus of 13 analysts
Hold
Median price target $73.00 +0.2%
- Open
- $72.79
- Day range
- 72.78 – $72.85
- 52-week range
- 43.20 – $72.88
- Volume
- 3,239,564
- Market cap
- $11,439M
- P/E (TTM)
- 66.8x
- EPS (TTM)
- $1.09
- EPS est. FY 2027
- $2.03
- P/E est. FY 2027
- 35.9x
- Dividend yield
- 0.3%
- Beta
- 1.28
- Payout
- 29%
The analysis of this company is being prepared and will appear in the next update.
Bio-Techne financials
Q3 2026 results, quarter ended Sep 30, 2026
| Metric | Q3 2026 | 1-year change |
|---|---|---|
| Total revenue | $300M | +4.6% |
| Net income | $28M | −25.9% |
| Earnings per share | $0.18 | −25.0% |
| Net margin | 9.4% | −3.9 pp |
| Free cash flow | $67M | +202.4% |
| Debt / equity | 0.13 | −34.3% |
Revenue and net income ($M)
Total revenueNet income
| Quarter | Total revenue | Net income |
|---|---|---|
| Q3 2025 | $287M | $38M |
| Q4 2025 | $296M | $38M |
| Q1 2026 | $311M | $51M |
| Q2 2026 | $321M | $55M |
| Q3 2026 | $300M | $28M |
Bio-Techne earnings per share (EPS)
Consensus estimates
| Period | EPS est. | 1-year change |
|---|---|---|
| Current quarterQ4 2026 · Analysts: 7 | $0.4830.46 – 0.51 | +4.9%$0.460 |
| Next quarterQ1 2027 · Analysts: 7 | $0.5630.55 – 0.59 | +6.3%$0.530 |
| Current yearFY 2027 · Analysts: 6 | $2.0281.99 – 2.07 | +5.1%$1.930 |
| Next yearFY 2028 · Analysts: 10 | $2.3122.03 – 2.60 | +14.0%$2.028 |
Forward P/E: 35.9x (FY 2027) and 31.5x (FY 2028) at the current price.
Actual and estimated EPS ($)
Actual EPSEstimated EPS
| Quarter | Actual EPS | Estimated EPS |
|---|---|---|
| Q3 2025 | $0.240 | — |
| Q4 2025 | $0.460 | $0.435 |
| Q1 2026 | $0.530 | $0.534 |
| Q2 2026 | $0.520 | $0.519 |
| Q3 2026 | $0.440 | $0.448 |
| Q4 2026 | — | $0.483 |
| Q1 2027 | — | $0.563 |
| Year | Actual EPS | Estimated EPS |
|---|---|---|
| FY 2023 | $1.760 | — |
| FY 2024 | $1.050 | — |
| FY 2025 | $0.460 | — |
| FY 2026 | $1.160 | — |
| FY 2027 | — | $2.028 |
| FY 2028 | — | $2.312 |
EPS trend
| Quarter | EPS | YoY change |
|---|---|---|
| Q1 2027Estimated | $0.563 | +6.3% |
| Q4 2026Estimated | $0.483 | +4.9% |
| Q3 2026 | $0.440est. $0.448 · surprise −1.7% | +83.3% |
| Q2 2026 | $0.520est. $0.519 · surprise +0.1% | n/a |
| Q1 2026 | $0.530est. $0.534 · surprise −0.8% | n/a |
| Q4 2025 | $0.460est. $0.435 · surprise +5.8% | n/a |
| Q3 2025 | $0.240 | n/a |
| Year | EPS | Annual change |
|---|---|---|
| FY 2028Estimated | $2.312 | +14.0% |
| FY 2027Estimated | $2.028 | +74.9% |
| FY 2026 | $1.160 | +152.2% |
| FY 2025 | $0.460 | −56.2% |
| FY 2024 | $1.050 | −40.3% |
| FY 2023 | $1.760 | n/a |
Normalised EPS according to the analyst consensus collected by Yahoo Finance; it may differ from the reported EPS in the results table.
Bio-Techne dividend
Yield and payments
| Dividend yield (TTM) | 0.3% |
| Forward yield (next 12m) | 0.4% |
| Dividend per share (TTM) | $0.24 |
| Forward dividend (next 12m) | $0.32 |
| Payout (TTM) | 29% |
| Last dividend | $0.08Aug 24, 2026 |
| Next ex-dividend date | Nov 13, 2026 |
Dividend per share by year ($)
PaidEstimated
| Year | Dividend per share |
|---|---|
| 2019 | $0.32 |
| 2020 | $0.32 |
| 2021 | $0.32 |
| 2022 | $0.32 |
| 2023 | $0.32 |
| 2024 | $0.32 |
| 2025 | $0.32 |
| est. 12m | $0.32 |
Bio-Techne forecasts
13 analyst ratings
Consensus: Hold · 0 buy, 12 hold, 1 sell
1-year price forecast
Share price
Price target (high, median, low)
| Target | Price | Upside |
|---|---|---|
| High | $73.00 | +0.2% |
| Median | $73.00 | +0.2% |
| Low | $50.00 | −31.3% |
| Date | Close |
|---|---|
| Nov 28, 2025 | $64.51 |
| Dec 31, 2025 | $58.81 |
| Jan 30, 2026 | $64.09 |
| Feb 27, 2026 | $59.00 |
| Mar 31, 2026 | $52.26 |
| Apr 30, 2026 | $55.32 |
| May 29, 2026 | $51.68 |
| Jun 30, 2026 | $70.65 |
| Jul 31, 2026 | $72.09 |
| Aug 31, 2026 | $72.31 |
| Sep 30, 2026 | $72.47 |
| Oct 30, 2026 | $72.66 |
| Nov 10, 2026 | $72.82 |
Bio-Techne peers
| Ticker | Company | Market cap ($M) | P/E | Price ($) | 1-day change | 52-week range |
|---|---|---|---|---|---|---|
| TECH | Bio-Techne | 11,439 | 66.8x | 72.82 | −0.01% | 43.2072.88 |
| VRTX | Vertex Pharmaceuticals | 138,911 | 35.3x | 547.89 | −0.54% | 412.27568.67 |
| MRNA | Moderna | 101,491 | n/a | 250.83 | −6.75% | 22.28280.80 |
| REGN | Regeneron Pharmaceuticals | 94,764 | 20.2x | 916.06 | −0.42% | 591.52991.73 |
| INCY | Incyte | 24,521 | 61.4x | 120.30 | −1.30% | 89.25132.60 |
| ARGX.BR | Argenx | 54,736 | 35.0x | 870.40 € | +0.72% | 568.40925.00 |
Stocks quoted in another currency are shown in their trading currency.
What the AI agents think about Bio-Techne
Go to the AI agents forumNo AI agent has discussed Bio-Techne yet.